MetaCap

Cingulate Inc. (CING)

NASDAQ: CINGHealth CareBiotechnology: Pharmaceutical PreparationsUSD

4.51-0.75 (-14.26%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CING stock chart

Technical analysis

Key statistics

All statistics
Market cap
$67.48M
EPS (TTM)
-$2.67
52-week range
3.16 – 11.89
Day range
4.40 – 5.24
Volume / Avg
973.91K / 178.82K
Beta
—

52-week range

$3.16$11.89

CING stock today

Shares of Cingulate (CING) finished lower on Nov 20 at $4.51, a drop of 14.26% or $0.75 per share, versus the S&P 500's 3.70% decline. Volume was 5.4x the average at 973.91K shares, a sign of unusually heavy trading. Shares are 62.1% below their 52-week high of $11.89, set on Mar 17, 2026 and 42.7% above the 52-week low of $3.16, near the bottom of the past year's range.

CING is up 3.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 27.8%. Cingulate has posted a net loss over the last twelve months (EPS of -$2.67), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Cingulate

Company profile

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Shane J. Schaffer Pharm.D.
Headquarters
Kansas City, KS
Employees
14
IPO year
2021

Financial highlights

Full financials

Cingulate reported a net loss of $22.4 million, compared with a loss of $16.6 million a year earlier. Diluted earnings per share came in at -$4.44.

Cingulate annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-22.45M$-16.56M$-23.53M$-17.68M$-20.71M
EPS (diluted)$-4.44$-10.86$-311.99$-29.35$-2.79

Analyst forecast

Forecast

Consensus (4 analysts)

none

Avg. price target

$21.20+370.07%

  • Strong buy 1
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $8.00High $44.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.53 vs $-0.48
Surprise
-10.42%

CING news

All CING news

Cingulate peers

Health Care sector
CING peer companies
CompanyPrice% ChgMarket capCompare
MNOVMedicinova Inc1.31+3.15%$67.11Mvs CING
MAIAMAIA Biotechnology Inc.1.11-2.63%$68.54Mvs CING
PLYXPolaryx Therapeutics Inc.1.33-11.92%$66.30Mvs CING
PMVPPMV Pharmaceuticals Inc.0.876-33.13%$66.17Mvs CING
COYACoya Therapeutics Inc.2.95-1.01%$69.20Mvs CING
GOSSGossamer Bio Inc.10.72-4.54%$65.57Mvs CING
ZYBTZhengye Biotechnology Holding Limited Class A1.48-2.63%$70.14Mvs CING
FBIOFortress Biotech Inc.1.90+7.34%$64.11Mvs CING

Indexes, lists and sector

Cingulate stock FAQ

What is Cingulate's stock price today?

CING last traded at $4.51 as of Nov 20, 4:00 PM EST, down 14.26% on the day. Prices are delayed at least 15 minutes.

Does Cingulate pay a dividend?

No. Cingulate does not currently pay a regular cash dividend.

Who is Cingulate's CEO?

Dr. Shane J. Schaffer Pharm.D. is the chief executive officer of Cingulate Inc., which has about 14 employees.

Has CING ever split its stock?

Yes. The most recent CING stock split was a 1-for-12 split on Aug 9, 2024, one of 2 splits on record.

What is the CING 52-week high?

The 52-week high for CING is $11.89 and the 52-week low is $3.16. The stock is currently 62.1% below its high.

Compare CING